IOL Chemicals planning to invest Rs 200 crore over next two years

14 Nov 2017 Evaluate

IOL Chemicals & Pharmaceuticals is planning to pump in about Rs 200 crore over the next two years in expanding its existing manufacturing capacities including its flagship product, Ibuprofen from 7200 TPA to 12000 TPA, keeping in view the recent approvals from US and Europe.

Presently, the company is also in the process of setting up of a Greenfield facility of producing anti-diabetic product i.e Metformin, at Barnala, Punjab with a capex of Rs 10 crore which will be met from internal accruals and likely to be completed during current financial year.

The company has recently enhanced Ibuprofen capacity from 6200 TPA to 7200 TPA, which is adequately used presently. The company has also completed and commercialized Unit III to manufacture Fenofibrate, Clopidogrel and Lamotrigine etc. with an investment of Rs 16.48 crore met through internal accruals.

The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), EDQM, WHO. The company is already exporting its Ibuprofen in regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc and with the approval from USFDA, the company is exploring its business in USA.



IOL Chem & Pharma Share Price

81.86 -2.67 (-3.16%)
08-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×